Supporting Information

Unveiling biosynthesis of the phytohormone abscisic acid in fungi: Unprecedented mechanism of core scaffold formation catalyzed by an unusual sesquiterpene synthase

Junya Takino¹, Takuto Kozaki¹, Yoshiro Sato¹, Chengwei Liu¹, Taro Ozaki¹, Atsushi Minami¹*, and Hideaki Oikawa¹*

¹Department of Chemistry, Faculty of Science, Hokkaido University, Kita-ku Kita 10 Jo Nishi 8 Chome, Sapporo 060-0810, Japan.

Table of Contents

Figures	
Figure S1: Schematic view of the abscisic acid biosynthetic gene cluster	Page S5
Figure S2: Comparison of BcABA-S and BcABA-L sequences	Page S6
Figure S3: GC-MS chromatograms of the headspace volatile organic compo	ounds
	Page S7
Figure S4: SDS-PAGE analysis of BcABA3	Page S7
Figure S5: GC-MS chromatograms of the enzymatic reaction products	Page S7
Figure S6: GC-MS chromatograms of the products from in vivo biotransform	mation
	Page S8
Figure S7: NMR spectra of deuterium labeled 2	Page S8
Figure S8: MS spectra of deuterium labeled 1	Page S9-10
Figure S9: Proposed deprotonation-protonation sequence	Page S11
Figure S10: Proposed stereochemical course of the BcABA3-catalyzed cycl	ization
	Page S11
Figure S11: Alignment of amino acid sequences of BcABA3 homologs	Page S12
Schemes	
Scheme S1: Proposed biosynthetic pathway of abscisic acid in <i>B. cinerea</i> .	Page S13
Scheme S2: Proposed biosynthetic pathway of abscisic acid in <i>C. cruenta</i> .	Page S13
Scheme S3: Alternative mechanism catalyzed by BcABA3.	Page S13
	-
Tables	
Table S1: Oligonucleotides used for construction of expression plasmids	s Page S14

General.

All reagents commercially supplied were used as received. Column chromatography was carried out on 60N silica gel (Kanto Chemicals). Optical rotations were recorded on JASCO P-2200 digital polarimeter. ¹H- and ²H-NMR spectra were recorded on Bruker DRX-500 or Bruker AMX-500 spectrometer (500 MHz for ¹H-NMR). NMR spectra were recorded in CDCl₃ (99.8 atom% enriched, Kanto) and CHCl₃ (Kanto). ¹H chemical shifts were reported in δ value based on residual chloroform (7.26 ppm) as a reference. GC-MS and UPLC analyses were conducted with a MS-2010 (Shimadzu) and a Waters ACQUITY UPLC, respectively.

Oligonucleotides for polymerase chain reactions (PCRs) were purchased from Hokkaido System Science Co., Ltd. PCRs were performed with a BioRad S1000 thermal cycler.

Strain and culture conditions.

Escherichia coli HST08 was used for cloning and following standard recombinant DNA techniques. *E. coli* BL21-Gold(DE3) was used for protein expression. *Botrytic cinerea* MAFF 306914 from NARO genebank, Japan was used for extraction of genomic DNA. Sequences of *bcABA1, bcABA2, bcABA3* and *bcABA4* from MAFF 306914 are nearly identical to those of strain B05.10. A fungal host strain used in this study was *A. oryzae* NSAR1, a quadruple auxotrophic mutant (*niaD*⁻, *sC*⁻, *AargB, adeA*⁻), for fungal expression.

Genomic DNA preparation.

Genomic DNA of *B. cinerea* MAFF 306914 was extracted according to the following method; the mycelia of fungus was collected and dried using paper towel. The dried mycelia was frozen in liquid nitrogen and crushed by SK-mill (Tokken). To the frozen powder was added extraction buffer (400 mM of Tris-HCl (pH 8.0), 500 mM of NaCl, 20 mM of ethylenediaminetetraacetic acid (EDTA) and 1% of sodium dodecyl sulfate) and the suspension was kept at room temperature for 5 min. To the suspension was added phenol:chloroform solution and the mixture was vortexed for 2 sec. After incubation at 65 °C for 60 min, the reaction mixture was centrifuged at 12000 rpm for 5 min. The supernatant was then treated with RNase at 37 °C for 90 min. To the reaction mixture was then added phenol:chloroform solution. After being vortexed for 2 sec, the mixture was centrifuged at 12000 rpm for 5 min. The supernatant was transferred to a new centrifuge tube and re-extracted twice with phenol:chloroform solution followed by chloroform. To the final supernatant was added cold-isopropanol and CH₃COONa solution and genomic DNA was recovered by centrifugation at 12000 rpm for 10 min. The pellet was then washed with 70% ethanol solution and dried for 15 min. Finally, the isolated DNA was resuspended in TE buffer (10 mM of Tris-HCl (pH 8.0) and 1mM of EDTA) and stored at -20 °C for further use.

Construction of E. coli expression plasmids.

Previous mRNA analysis showed that the *bcABA3-L* has no intron. Therefore, it was amplified from genomic DNA of *B. cinerea* MAFF 306914 with primer set as shown in Supplemental Table S1. PCR reactions were performed with the KOD-Plus-Neo (TOYOBO). Each PCR product was

inserted into *Nde*I site of pColdI using In-Fusion Advantage PCR cloning kit (Clontech Laboratories) to construct expression plasmid pColdI-*bcABA3-L*. The sequence *bcABA3* from MAFF 306914 was identical to that of B05.10. The expression plasmid pColdI-*bcABA3-S* was constructed by using PrimeSTAR Mutagenesis Basal Kit (Takara) with primer sets, *bcABA3m-F* and *bcABA3m-R*, according to the manufacturer's protocol. These plasmids were separately introduced into *E. coli* BL21-Gold(DE3) for overexpression. The transformant was grown at 37 °C at an OD₆₀₀ of ~0.6 in 500 mL flask. After cooling at 4 °C, isopropyl β-D-thiogalactopyranoside (0.1 mM) was added to the culture. After incubation at 16 °C for 17 h, the cells were harvested by centrifugation at 4000 rpm. Harvested cells were resuspended in disruption buffer (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM imidazole, 5 mM MgCl₂) and disrupted by sonication. After centrifugation, the supernatant was applied to a Ni-NTA column to purify the BcABA3-L.

BcABA3 Assays (in vitro).

Typical conditions are as follows; a reaction mixture (100 μ L of Tris-HCl buffer (pH 7.4)) containing 130 μ M of FPP, 0.5 mM of EDTA, 5 \Box M of MgCl₂, 2 mM of DTT, 2 μ g of BcABA3 was incubated at 30 °C for 1 hr. The reaction was quenched by the addition of Hexane (50 μ L) and the resultant mixture was vortexed and centrifuged at 12,000 x g. The supernatant was directly analyzed by a GC-MS QP2010 apparatus (Shimadzu, Kyoto, Japan) with a DB-1 MS capillary column (0.32 mm × 30 m, 0.25 \Box m film thickness; J&W Scientific, Folsom, CA). Each sample was injected onto the column at 100 °C in the splitless mode. After isothermal hold at 100°C for 3 min, the column temperature was increased by 14°C min⁻¹ to 268°C. The flow rate of the helium carrier gas was 0.66 mLmin⁻¹.

BcABA3 Assays (in vivo).

The transformant EC-*bcABA3-L* was grown at 37 °C at an OD₆₀₀ of ~0.6 in 500 mL flask in the presence of fosmidomycin (5.5 μ M). After cooling at 4 °C, isopropyl β -D-thiogalactopyranoside (0.1 mM) was added to the culture. After incubation at 16 °C for 17 h, the cells were harvested by centrifugation at 4000 rpm. Harvested cells were resuspended in 100 mM of phosphate buffer (pH 7.4). To the cell suspension was added β -farnesene or allofarnesene¹ (1 μ g) at 16 °C for 17 h. During those periods, the volatile organic compounds were extracted by a SPME fiber (50/30um DVB/CAR/PDMS. Stableflex, 24Ga, Manual Holder), which was conditioned by inserting it into the GC injector to prevent contamination. After extraction, the fiber was pulled into the needle sheath and the SPME device was removed from the vial and then inserted into the injection port to analyze the sample.

Construction of A. oryzae expression plasmids.

The *bcABA1-bcABA4* were amplified from genomic DNA of *B. cinerea* MAFF 306914 with primer set as shown in Supplemental Table S1. PCR reactions were performed with the KOD-Plus-Neo (TOYOBO). Each PCR product was inserted into appropriate restriction site (site 1 and/or site 2) of pTAex3², pUSA2³, or pAdeA2⁴ using In-Fusion Advantage PCR cloning kit

(Clontech Laboratories) or NEBuilder HiFi DNA Assembly cloning kit (NEW ENGLAND BioLabs) to construct expression plasmids pTAex3-*bcABA1*, pUSA2-*bcABA24*, and pAdeA2-*bcABA3*.


Transformation of Aspergillus oryzae.

Transformation of *A. oryzae* NSAR1 (1.0×10^8 cells) was performed by the protoplast-polyethylene glycol method reported previously⁵ to construct AO-*bcABA1234*.

Analysis of the metabolites.


Mycelia of AO- *bcABA1234* was inoculated into a MPY medium (2 mL) in 10 mL test tube. Each culture was incubated at 30 °C for 4 days. The fermentation broth was soaked in acetone (2.5 mL) for 12 hr. After filtration, the filtrate was concentrated in vacuo. The residual water was adjusted to pH 1.0 and then extracted with EtOAc, and the organic layers were concentrated in vacuo. This crude extracts were directly analyzed by a UPLC-MS equipped with a ACQUITY UPLC BEH C10 (ϕ 2,1 x 50 mm) at the following conditions (conditions 1): flow rate; 0.7 mL/min, solvent system; acetonitrile in H₂O containing 0.1% of formic acid, 0-1 min: 10%; 1-3 min: a linear gradient 10%-95%; 3-5 min: 95 %).

Figure S1. Schematic view of the abscisic acid biosynthetic gene cluster in several fungi. The accession number and the identity of each BcABA3 homolog are summarized in the table.



Strain	Accession number	identity (%)
Rutstroemia sp. NJR-2017a BBW	PQE10665.1	86
Colletotrichum higginsianum IMI 349063	XP_018158055.1	70
Pseudogymnoascus sp. WSF 3629	OBT40576.1	67
Eutypa lata UCREL1	EMR65886.1	69
Leptosphaeria maculans JN3	XP_003843016.1	67
Amycolatopsis mediterranei S699	AEK46506.1	65
Aspergillus tubingensis CBS 134.48]	OJI80076.1	63
Pyrenophora tritici-repentis Pt-1C-BFP	XP_001939959.1	63
Pyrenophora teres f. teres 0-1	EFQ89822.1	61
Exophiala xenobiotica	XP_013319909.1	60
Elsinoe australis	PSK60221.1	58
Alternaria alternata	XP_018379073.1	55
Stemphylium lycopersici	KNG44597.1	51
Fusarium oxysporum f. sp. lycopersici 4287	XP_018257345.1	52
Streptomyces sp. NRRL F-6131	WP_030303341.1	51

(A) Alignment of genomic DNA sequences of *bcABA-L* (B05.10 strain, XM_024694602.1) and *bcABA-S* (SAS56 strain, AM237449.1)



(B) Alignment of BcABA-S (SAS56 strain, CAJ87067.1) and BcABA-L (B05.10 strain, XP_024550392.1)

CAJ87067.1	MQQVITQTLVDDRFIQISDSKKSEGLATDSTKRQSQEQPIHDKDPIKAATAAMATTPLVK
XP_024550392.1	MQQVITQTLVDDRFIQISDSKKSEGLATDSTKRQSQEQPIHDKDPIKAATAAMAATPLVK
CAJ87067.1	EHQDTWYYPPDIANDLQSINLPAELKGEIFACAWEYTRCVIPNYTNWNRYVAFMRIIIMG
XP_024550392.1	EHQDTWYYPPDIANDLQSINLPAELKGEIFACAWEYTRCVIPNYTNWNRYVAFMRIIIMG
CAJ87067.1	IIAEFRGEMVDVTASNNLLGYDLDATLAALFEGTPGHKEMAREYKTFLLITADKASERRD
XP_024550392.1	IIAEFRGEMVDVTASNNLLGYDLDATLAALFEGTPGHKEMAREYKTFLLITADKASERRD
CAJ87067.1	GELFRRYVNALAQSPRHWFRMRDCDALARFTIASALACNDLDDIWFTEDQFEILTEIGDT
XP_024550392.1	GELFRRYVNALAQSPRHWFRMRDCDALARFTIASALACNDLDDIWFTEDQFEILTEIGDT
CAJ87067.1 XP_024550392.1	LYDAVAFYKHRAEGETNSTFAYMPEDLRIKAYSECREILWALDAAWARNPKLANVINFVR LYDAVAFYKHRAEGETNSTFAYMPEDLRIKAYSECREILWALDAAWARNPKLANVINFVR ************************************
CAJ87067.1	FFGGPIHMMMRRYRFVEENLTIGKSETDKVVDQTRKNFKLWNRVDANKRSVLNTQRYKAL
XP_024550392.1	FFGGPIHMMMRRYRFVEENLTIGKSETDKVVDQTRKNFKLWNRVDANKRSVLNTQRYKAL
CAJ87067.1 XP_024550392.1	IARSEELMFPGLAEFLEMGGDGICDKCKYRESTVQNCHTSLVV IARSEELMFPGLAEFLEMGGDGICDKCKYRESYGAELSHQFGGVELCSECRLSWRKYLEC ************************************
CAJ87067.1 XP_024550392.1	LNYAANADYRGEST FVERATKVFPELKTHFEVPV : *. : .*

Figure S3. GC-MS chromatograms of the headspace volatile organic compounds from (A) EC-*WT*, (B) EC-*bcABA3*, and (C) EC-*amABA3*.




Figure S4. SDS-PAGE analysis of BcABA3. M: marker and lane 1: purified BcABA3.




Figure S5. GC-MS chromatograms of the enzymatic reaction products: (A) without BcABA3, (B) in the presence of EDTA (20 mM), and (C) with BcABA3.




Figure S6. GC-MS chromatograms of the products from in vivo biotransformation (D) without substrate (m/z 148), (E) with 4 (m/z 135 and 148), and (F) with 5 (m/z 148).





Figure S7. (A) ¹H-NMR spectrum (0.5 - 7.5 ppm) of **2**. (B) ²H-NMR spectrum of **2** prepared by enzymatic reaction in the presence of 90% D₂O.



	$FPP F_{148}^{(+0)} (+0) = M^{+}(+0)$
	$F_{133}(+0) = F_{148}(+0) = F_{148}(+0) = F_{133}(+0) = F_{148}(+0) = F_{133}(+0) = $
	$4S-D-FPP \xrightarrow{F_{148}(+1)} M^{+}(+1)$
135 150 92 107 121 92 107 121 206	$F_{133}(+1) = F_{133}(+1) = $
92 ¹⁰⁷ 120 92 ¹⁰⁷ 120 205	$5-D_2$ -FPP $F_{148}(+1)$ $M^*(+1)$ F ₁₃₃ (+1) -
133 148 91 105 119 204	$F_{133} (+1) = $
92 107 120 92 107 120 205	1,5-D ₄ -FPP F ₁₄₈ (clustered) F ₁₃₃ (clustered) M ⁺ (clustered)
133 151 91 105 119 101 105 119 207	$\begin{array}{c} \begin{array}{c} CD_{3} \\ 13 \cdot D_{3} \cdot FPP \end{array} \xrightarrow{F_{148}(+3)} \begin{array}{c} \\ F_{148}(+3) \end{array} \xrightarrow{CD_{3}} M^{+}(+3) \end{array}$
133 91 107 122 207	F133 (+0) F_{133} (+0) F_{133} (+0) F_{133} F_{1
136 151 95 110 122 	$F_{133} \text{ (clustered)} \qquad \qquad$
108 108 108 122 122 122 210 60 80 100 120 140 160 180 200 220 (m/2)	$FPP = F_{148} (clustered) = F_{133} (clust$

Figure S8. MS spectra of deuterium labeled 1. The observed mass shifts are shown in the parenthesis.




Figure S9. Proposed deprotonation-protonation sequence of β -farnesene via $A2^+$ and B^+ .




Figure S10. Proposed stereochemical course of the BcABA3 catalyzing cyclization via (A) a chair conformation and (B) a boat conformation.






Figure S11. Alignment of amino acid sequences of homologous enzymes with BcABA3. Highly conserved regions are shown in region 1 to region 3.

KNG44597.1 EXK82261.1 WP_030303341. PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OBT40576.1	MPKATTESHIRTYTSISHTKM 	XP_018379073.1 KNG44597.1 EXK82261.1 WP_0300334.1 PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OB140576.1 XP_018158055.1 BcABA3 XP_003843016.1	Fight 3 Firty Fight 11 Mark Reverse 12 First 6 for the first firs	QKKTK DIVK NTAA KNGGK DIHD-SNGEGQ TEKS NKRG TTRVAGSSSSGS NKRS
KNG44597.1 EXK82261.1 WP_030303341. PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OBT40576.1	AVVVHERWYYPPDIANDL&DI-DLPDRVKQEIFATAWEYTRCVIPEYTNWSRYVAFMRII 	XP_018379073.1 KNG44597.1 EXK82261.1 WP_0303341.1 PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OB140576.1 XP_018158055.1 BCABA3 XP_003843016.1	KQETESLQQYRHVLS-REXILLFNGLGEMLEKADEGLCSECSYRETYGJ QQELESLQQYRQVLS-QEKVLLFNGLGAMLEKADEDLCSKCTYRETYGJ PDRDGRYHDTIT-KLDKIMLFGCSLLESSARKHCSYCSNAVSSG PDRENTDAVVR-QARLFPGARELLSRPDGKK-PHCRRLSYGJ QENSSRYKEIISHSEDLMYFGLAHALETAFTGCTDCYFRSSGJ EESSPDVQRYKHLIQNHTQDLMYTELDEFLEHSDDSTCTDCFRRSYGJ TIEASSIGYHAVLE-RSEELMFFGLPELLERGSRPHCDRCLYRASYGJ VNDTRYKNLLA-GSELMFFGLAPLLESGADAHCDHCRHRLSYGJ PSCNQSVQRYKDLIA-RSEELMFFGLAPLESGADGCCDKCKYRESYGJ VNDTRYKNLLA-RSEELMFFGLAPLESGADGCCDKCKYRESYGJ PSCNQSVQRYKDLVANRSGDLMFFGLAPLESGADGGCCDKCKYRESYGJ AGDEKRYKDIYSANSEVMFFGLAPLENM-EDNCPCFRESYGJ 	LPQAHTFGGVTL DD-IRFGGVRL LEAACEFGCVEL LQGVGEFGGVQL LEQNHSFGGVAL LEPLGFFGGVAL LEFLGFFGGVEL LEFSHEFGGVEL LELSHQFGGVEL LELSHQFGGVEL
KNG44597.1 EXK82261.1 WP_030303341. PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OBT40576.1 XP_018158055.1 BcABA3	VMGIIAEFKGSLMDVANDDNVVGYSLTEVLDTLCGGTAGHAEMCREYRCFLLMSSQKSRH VMGIIAEFRGSLMDVANDDNVVGYSLTEVLNTLCGGTAGHV- IIATVAEFRGJLPEINSKNIIGVDLDELSTLFGGTSMREDMSREFFRTFLLMSAEKSRK ATAVAEVFGEHVULSEGPVLGYDVDDLLDTLFTROSAVREDMSREFFRAMLLSTEKSG IVAVIAEYRGHUVVLSEGDVLGYDVDDLLDTLFTROSAVREDMSREFFRAMLLMTGRKTSE IIGVICEFSGDMINVAESRKMLGYDVDQULDALFKGTPGHEAMSREFFRAFLLIVTGAKTSE INGIIAEFRGGLVDVAAGDNLLGVDLEDLTVFATFGETFGHALMAREYKTFLLTADKSSE IIGVICEFSGDMINVAESRKMLGYDVGSTLATLFEGTFGHTDMAREYKSFLLTADKSSE IIGIIAEFRGSLVDVSASDNIHGYDLGSTLATLFEGTFGHTDMAREYKSFLLTADKSSE IIGIIAEFRGSLVDVSASDNIHGYDLGSTLATLFEGTFGHTDMAREYKSFLLTADKSSE IIGIIAEFRGSLVDVTAGDNILGYDLGATLAALFFGTFGHTEMAREYKTFLLTADKSSE IIGIIAEFRGSLVDVTAGDNILGYDLGATLAALFFGTFGHTEMAREYKTFLLTADKSSE IIGIIAEFRGSLVDVTAGDNILGYDLGATLAALFFGTFGHTEMAREYKTFLLTADKSSE IIGIIAEFRGSLVDVTAGDNILGYDLGATLAALFFGTFGHTEMAREYKTFLLTADKSSE IIGIIAEFRGSLVDVTAGDNILGYDLGATLAALFFGTFGHTEMAREYKTFLLTADKSSE	XP_018379073.1 KNG44597.1 EXK82261.1 WP_033030341.1 PSK60221.1 XP_013319909.1 EMR65886.1 AmABA3 OBT40576.1 XP_018158055.1 BcABA3 XP_003843016.1	CAAHRQGWADHTESILERMVRSFPEAAETVRISENRATRSAAP CASCOQGWCAYTETVLERMARSFPEAAETIRISENRATCLIAP CDECKANWRSFWLARARFARAAFFEINRUKUKGWCCGSSS CPACREQWRQYLEALPQRVIEVFPEVLDVPGPSRS CRCKVWAGALLESFFKRILEAFFELKGFEGFT CRCCQAMMRGYUESLEDRTKEVFAGTULKAPSGGEVAGHNRGINNQOV CDSCRADWRTLENFFRAREVFLEVEVDAI CDGCRSTWWALLESFFKRARVVLEVILVEVR CDDCRAGWRAYLESFPERARVVFEILEVKPD CDCCRSTWWALLESFFERARVVFEILEVKPD CDCCRSTWWALLESFFERARVVFEILEVKPD CDCCRSTWRKLECFVERATVVFFELKVHEF CSCRLSWKKLECFVERATVVFFELKTHFEV 	N
KNG44597.1 EXK82261.1 WP 03030341. PSK60221.1 VP_013319909.1 ENR65886.1 AmABA3 OBT40576.1 BcABA3 XP_003843016.1 XP_018379073.1 KNG44597.1 EXK82261.1 WP_03303341. PSK60221.1 AmABA3 OBT40570.1 XP_018158055.1 EcABA3	regin 1 OTTIMLFRYSVALSKS PWOFFRMRDTDALARTTIGVALVCNDLDHINFTNDQFDINAEI ALSKS PWOFFRMRDTDALARTTIGVALVCNDLDHINFSEDGFDINAEI ORDSELFGRYLNALAKSPOWNFRLRDCCALARTTIGVALVCNDLDHINFSEDGFDINAEI RRGELFRRYVVALASSPOWNFRLRDCCALARTTIASALACNOLDUVFEDQFELIAEI RRGELFRRYVVALASSPOWNFRLRDCCALARTTIAGLSCNDHDDVYFSDAGFILIAEI RRGELFRRYVNALASSPOWNFRLRDGALARTTIAGLACNDHDDVYFSDAGFILIAEI RRGELFRRYVNALASSPONFRRHDCALARTTIAGLSCNDHDDVYFSDAGFILIAEI RRGELFRRYVNALASSPONFRHRDCALARTTIASALACNDLDDVMPTOQFELLAEI RCGGLFRRYVNALASSPONFRHRDCALARTTIASALACNDLDDVMPTOQFELLEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDVMPTOQFELLEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDVMPTOQFELLEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDVMPTOQFELLEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHNRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFRHNRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTTIASALACNDLDDLMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTTIASALACNDLDIMPTEOFFILTEI RRGGELFRRYVNALASSPONFFRHRDSALARTIASALARTIASALACNDLDIMPTEOFFILTEI RDGINT	XP_018379073.1 KNG44597.1 EXK82261.1 WP_0300334.1 PSK60221.1 XP_01319909.1 EMR65886.1 AmABA3 OBT40576.1 XP_018158055.1 BcABA3 XP_003843016.1	GRHSNDDDFPSLPNGNAPLQNGHANGAVLVAVME	442 339 399 375 406 404 443 387 416 484 440 346

Scheme S1. Proposed biosynthetic pathway of abscisic acid in *B. cinerea*.



Scheme S2. Proposed biosynthetic pathway of abscisic acid in *C. cruenta*. Incorporation ratios of each compound are shown below the structure.



Scheme S3. Alternative mechanism catalyzed by BcABA3.




 Table S1. Oligonucleotides used for construction of expression plasmids.

Insert	Sequence 5'-3'	Size
	Sequence 5 -5	Vector
L = ADA1	F: CAAGCTCCGGAATTCATGTCTAATTCTATATTG	1769 bp
bcABA1	R: TACCGAGCTCGAATTCCTATTTGTATTCTGTTC	pTAex3
h = ADAD	F: AATTCGAGCTCGGTACATGCTGCTTAGCATTAAAG	1810 bp
bcABA2	R: CTACTACAGATCCCCGGCTATCTAGGAACCTCTTTTAAC	pUSA2
linkou	F: AGAGGTTCCTAGATAGCCGGGGGATCTGTAGTAGCTC	860 bp
linker	R: ATGGTTGAGAGGACATTGCGGCCGCTAGCTCAAATC	pUSA2
bcABA4	F: TGAGCTAGCGGCCGCAATGTCCTCTCAACCATTC	840 bp
	R: CTACCCGGGTCACTAGCTAACATCTCCATCCGCC	pUSA2
bcABA3-Ao	F: ATCGATTTGAGCTAGCATGCAGCAAGTTATTACTCAA	1323 bp
	R: TAGTGCGGCCGCTAGCTCAAACTGGAACCTCAAAATG	pAdeA2
bcABA3-Ec	F: ATATCGAAGGTAGGCATATGCAGCAAGTTATTAC	1323 bp
	R: GGGTACCGAGCTCCATATGTCAAACTGGAACCTCAAAATG	pColdI
bcABA3m	F: TCGCGAGTCTACGGTGCAGAATTGTCACACCAG	1254 bp
	R: ACCGTAGACTCGCGATATTTGCATTTGTCACAA	

[References]

- 1. Inomata, M.; Hirai, N.; Yoshida, R.; Ohigashi, H. Phytochemistry 2004, 65, 2667-2678.
- a) Fujii, T.; Yamaoka, H.; Gomi, K.; Kitamoto, K.; Kumagai, C. *Biosci. Biotechnol. Biochem.* 1995, 59, 1869-1874; b) Huang, K. X.; Fujii, I.; Ebizuka, Y.; Gomi, K.; Sankawa, U. J. *Biol. Chem.* 1995, 270, 21495-21502.
- 3. Tagami, K.; Minami, A.; Fujii, R.; Liu, C.; Tanaka, M.; Gomi, K.; Dairi, T.; Oikawa, H. *ChemBioChem* **2014**, *15*, 2076-2080.
- Ugai, T.; Minami, A.; Fujii, R.; Tanaka, M.; Oguri, H.; Gomi, K. Oikawa, H. Chem. Commun. 2015, 51,1878-1881.
- Liu, C.; Tagami, K.; Minami, A.; Matsumoto, T.; Frisvad, J. C.; Suzuki, H.; Ishikawa, J.; Gomi, K.; Oikawa, H. Angew. Chem. Int. Ed. 2015, 54, 5748-5752.